Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Tumor Lysis Syndrome Clear all
Recruiting Phase 3 Interventional

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT06428019
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Venetoclax, Acalabrutinib, Obinutuzumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
32
States / cities
Tucson, Arizona • Clovis, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 23, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Rasburicase in Patients at Risk for Tumor Lysis Syndrome

NCT00628628
View directory record Official record
Conditions
Tumor Lysis Syndrome
Interventions
As Needed Rasburicase, Fixed Dose Rasburicase
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Jul 23, 2026, 5:29 PM EDT
Completed Phase 4 Interventional

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

NCT00230217
View directory record Official record
Conditions
Tumors, Hyperuricemia, Tumor Lysis Syndrome
Interventions
Rasburicase (SR29142)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
Not listed
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
7
States / cities
Berkley, California • Denver, Colorado • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2009 · Synced Jul 23, 2026, 5:29 PM EDT
Terminated No phase listed Observational

Elitek (Rasburicase) Immuno-Monitoring Study

NCT01097369
View directory record Official record
Conditions
Tumor Lysis Syndrome
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
2 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Valhalla, New York • Oklahoma City, Oklahoma • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Jul 23, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

NCT00230178
View directory record Official record
Conditions
Tumor Lysis Syndrome, Cancer, Hyperuricemia
Interventions
Rasburicase (SR29142), Allopurinol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
15
States / cities
Berkeley, California • Los Angeles, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Jul 23, 2026, 5:29 PM EDT
Terminated Phase 1 Interventional

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

NCT04214093
View directory record Official record
Conditions
Advanced Solid Tumors, Lymphoma, Multiple Myeloma, Hematologic Malignancies
Interventions
AZD0466
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
New Haven, Connecticut • Boston, Massachusetts • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Jul 23, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

NCT03406156
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions
Obinutuzumab, Bendamustine, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
15
States / cities
Tempe, Arizona • Denver, Colorado • Kansas City, Missouri + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jul 23, 2026, 5:29 PM EDT
Completed Phase 4 Interventional

Fasturtec TLS Treatment / Prophylysis

NCT00651911
View directory record Official record
Conditions
Tumor Lysis Syndrome
Interventions
urate oxidase
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Jul 23, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

NCT01200485
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Rasburicase, Allopurinol
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Jul 23, 2026, 5:29 PM EDT
Completed No phase listed Observational

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

NCT02921828
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Not listed
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
No City Provided, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 4, 2022 · Synced Jul 23, 2026, 5:29 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS

NCT00360438
View directory record Official record
Conditions
Leukemia, Lymphoma, Tumor Lysis Syndrome
Interventions
Rasburicase
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Jul 23, 2026, 5:29 PM EDT
Completed Phase 4 Interventional

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

NCT04745910
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Tumor Lysis Syndrome
Interventions
Pegloticase, Rasburicase
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 23, 2026, 5:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma

NCT00445341
View directory record Official record
Conditions
Lymphoma
Interventions
Flavopiridol
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Jul 23, 2026, 5:29 PM EDT
Completed No phase listed Observational

Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

NCT00186940
View directory record Official record
Conditions
Leukemia, Lymphoma, Tumor Lysis Syndrome, Hyperuricemia
Interventions
Rasburicase
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
11
States / cities
Palo Alto, California • San Diego, California • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Jul 23, 2026, 5:29 PM EDT